BrainVol Cancer Research Results

BrainVol, Hippocampal Volume: Click to Expand ⟱
Source:
Type:
Brain volume is a key biomarker in Alzheimer’s disease (AD) and is closely associated with the progression of the disease
-AD is characterized by progressive brain shrinkage (atrophy)
-Hippocampus: One of the earliest and most affected areas; crucial for memory formation.
-Medial Temporal Lobe: Including the entorhinal cortex; important in converting short-term to long-term memory.
-Parietal and Frontal Lobes: Atrophy spreads here as the disease progresses, affecting language, spatial awareness, and executive function.
-MRI imaging is widely used to measure brain volume loss.
-Rate of volume loss can predict cognitive decline and transition from:
-Normal aging → Mild Cognitive Impairment (MCI) → Alzheimer’s Disease.

Rate of Brain Volume Loss
  Population Group	Estimated Brain Volume Loss / Year
  Healthy aging adults	~0.2–0.5%
  MCI patients	        ~1–2%
  AD patients	        ~2–3% or more



Scientific Papers found: Click to Expand⟱
6961- FA,  VitB12,  VitB6,  Silicon,  Alum  B Vitamins Prevent Iron-Associated Brain Atrophy and Domain-Specific Effects of Iron, Copper, Aluminum, and Silicon on Cognition in Mild Cognitive Impairment
- Trial, AD, NA
*BrainVol↝, Baseline iron, cysteine, and homocysteine were significantly associated with brain atrophy rate.
*cognitive↝, At baseline, iron, copper, aluminum, and silicon were significantly associated with one or more domains of cognition: semantic memory, verbal episodic memory, attention/processing speed, and executive function.
*cognitive↑, These factors showed domain-specific associations with cognition, which were abrogated by B vitamin therapy.
*Dose↝, daily folic acid (0.8 mg)/vitamin B12 (0.5 mg)/vitamin B6 (20 mg)
*other↝, Reducing the rate of brain atrophy is likely to slow the conversion of individuals with MCI to AD
*Hcy/homoC↓, Elevated plasma total Hcy (tHcy) is associated with brain atrophy in healthy elderly [6] and in AD patients [7].
*Risk↓, Silicon (Si) has been shown to prevent gastrointestinal absorption of Al [17]
*BrainVol∅, In contrast, we found no correlations between brain atrophy rate and baseline serum Cu, As, or Al
*BrainVol↑, B vitamin treatment abrogates associations of brain atrophy rate with Fe and Cys
*other↝, Baseline Fe, Cu, Al, and Si predict cognition in the placebo group at the end of study: multiple regression analysis
*cognitive↑, B vitamin treatment abrogates effects of Fe, Si, Al, and Cu on cognition
*cognitive↑, multiple regression analyses that baseline Fe and Si were associated with better performance in several domains of cognition at the end of study
*other↝, serum Fe levels were reduced [12] and serum Cu levels were elevated [11] in AD patients compared to healthy controls.
*Risk↝, In addition to Fe and Cu, Al is also known to accumulate in senile plaques [15] and a high daily intake of Al is associated with increased risk of dementia


Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Transcription & Epigenetics(tgid=7)

other↝, 3,  

Synaptic & Neurotransmission(tgid=18)

BrainVol↑, 1,   BrainVol↝, 1,   BrainVol∅, 1,  

Drug Metabolism & Resistance(tgid=21)

Dose↝, 1,  

Clinical Biomarkers(tgid=22)

Hcy/homoC↓, 1,  

Functional Outcomes(tgid=23)

cognitive↑, 3,   cognitive↝, 1,   Risk↓, 1,   Risk↝, 1,  
Total Targets: 10

Scientific Paper Hit Count for: BrainVol, Hippocampal Volume
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1372  State#:%  Dir#:4
wNotes=on sortOrder:rid,rpid

 

Home Page